Cell graft for severe damage to both eyes’ surface
Part of Eyes & vision clinical trials.
This Phase 1/2 trial tests a treatment made from your own mouth tissue cells to help regrow the front surface of the eye when both eyes have severe limbal stem cell deficiency. If you qualify, you may receive an autologous (made from your own tissue) cell sheet to improve eye healing and vision.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You can sign informed consent
- Both eyes have severe limbal stem-cell deficiency caused by injury, transplant, or another bilateral problem
- Your vision is very reduced (less than 2/10 or similar score)
- You are covered by a social security system
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new way to repair the eye surface by using a thin sheet of cells from your own mouth, which are grown in the lab and then placed on your eye. It may help people whose eye damage hasn't improved with other treatments and who have very poor vision.
This trial tests a treatment that uses your own eye cells to repair the surface of the eye. It may help if you have severe damage to the clear front layer of your eye.
This trial tests an eye treatment made from your own cornea surface cells, grown in a lab and put back into the eye. It may help people with limbal stem cell deficiency by improving the health of the eye surface after a cell biopsy.
This study tests a new treatment that uses your own stem cells to repair a damaged cornea after a chemical burn. It may help reduce scarring and improve vision.
This Phase 2 trial tests a locally delivered cell-based treatment (allogeneic mesenchymal stromal cells) to help heal long-lasting damage to the eye’s clear surface (the cornea). It may help if your cornea epithelium (surface layer) won’t improve even after standard non-surgical treatments.
This trial tests an investigational cell therapy called EO2002 for people with corneal edema (swelling of the clear front part of the eye) caused by endothelial dysfunction, which can happen with Fuchs dystrophy or after cataract surgery. The treatment aims to restore the inner layer of the cornea to reduce swelling and improve vision.
Hear when a new Total Bilateral Limbal Cell Deficiency trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.